These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36685552)

  • 1. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
    Mestre-Durán C; Martín-Cortázar C; García-Solís B; Pernas A; Pertíñez L; Galán V; Sisinni L; Clares-Villa L; Navarro-Zapata A; Al-Akioui K; Escudero A; Ferreras C; Pérez-Martínez A
    Front Immunol; 2022; 13():1045316. PubMed ID: 36685552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.
    Olson KC; Kulling Larkin PM; Signorelli R; Hamele CE; Olson TL; Conaway MR; Feith DJ; Loughran TP
    Cytokine; 2018 Nov; 111():551-562. PubMed ID: 30455079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection.
    Lang B; Wang M; Zhang Z; Fu Y; Han X; Hu Q; Ding H; Shang H; Jiang Y
    J Transl Med; 2023 Nov; 21(1):869. PubMed ID: 38037074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation.
    Gotthardt D; Trifinopoulos J; Sexl V; Putz EM
    Front Immunol; 2019; 10():2590. PubMed ID: 31781102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation.
    Hu X; Chen J; Wang L; Ivashkiv LB
    J Leukoc Biol; 2007 Aug; 82(2):237-43. PubMed ID: 17502339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
    Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
    J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells.
    Terrén I; Mikelez I; Odriozola I; Gredilla A; González J; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
    Front Immunol; 2018; 9():737. PubMed ID: 29713323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
    Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
    Vargas-Hernández A; Mace EM; Zimmerman O; Zerbe CS; Freeman AF; Rosenzweig S; Leiding JW; Torgerson T; Altman MC; Schussler E; Cunningham-Rundles C; Chinn IK; Carisey AF; Hanson IC; Rider NL; Holland SM; Orange JS; Forbes LR
    J Allergy Clin Immunol; 2018 Jun; 141(6):2142-2155.e5. PubMed ID: 29111217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
    Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
    Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors.
    Nishiya T; DeFranco AL
    J Biol Chem; 2004 Apr; 279(18):19008-17. PubMed ID: 14976215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.
    Marcuzzi A; Rimondi E; Melloni E; Gonelli A; Grasso AG; Barbi E; Maximova N
    Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway.
    Wang F; Zhang X; Liu W; Zhou Y; Wei W; Liu D; Wong CC; Sung JJY; Yu J
    Cell Mol Gastroenterol Hepatol; 2022; 13(1):257-274. PubMed ID: 34506952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation.
    Howell J; Sawhney R; Testro A; Skinner N; Gow P; Angus P; Ratnam D; Visvanathan K
    Liver Transpl; 2013 Oct; 19(10):1099-107. PubMed ID: 23894100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity.
    Lauzon NM; Mian F; MacKenzie R; Ashkar AA
    Cell Immunol; 2006 Jun; 241(2):102-12. PubMed ID: 17049504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
    Curran SA; Shyer JA; St Angelo ET; Talbot LR; Sharma S; Chung DJ; Heller G; Hsu KC; Betts BC; Young JW
    Cancer Immunol Res; 2017 Jan; 5(1):52-60. PubMed ID: 27923824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of TLR4/MyD88/p38MAPK and JAK/STAT pathway in RAW 264.7 cells by Alpinia galanga reveals its beneficial effects in inflammation.
    George G; Shyni GL; Abraham B; Nisha P; Raghu KG
    J Ethnopharmacol; 2021 Jul; 275():114132. PubMed ID: 33887419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells.
    Mäkelä SM; Strengell M; Pietilä TE; Osterlund P; Julkunen I
    J Leukoc Biol; 2009 Apr; 85(4):664-72. PubMed ID: 19164128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.